表紙
市場調查報告書

BCL-2(B細胞淋巴瘤2)抑制劑的全球市場:2019年∼2023年

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 905966
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
BCL-2(B細胞淋巴瘤2)抑制劑的全球市場:2019年∼2023年 Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023
出版日期: 2019年08月02日內容資訊: 英文 111 Pages
簡介

全球BCL-2(B細胞淋巴瘤2)抑制劑市場,由於老年人口的增加,骨髓惡性腫瘤相關意識的高漲,BCL-2抑制劑的高標的親和性與特異性等市場成長因素,在預測期間內預計將以約39%的年複合成長率擴大。但,替代品的可得性,BCL-2抑制劑的副作用,及藥物抗性等,可能妨礙在預測期間內BCL-2抑制劑產業的成長。

本報告提供全球BCL-2(B細胞淋巴瘤2)抑制劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 聯合治療
  • 單劑療法
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 患者支援計劃的增加
  • 策略性聯盟
  • 新製劑的開發

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31810

About this market

BCL-2 inhibitors are used as a targeted therapy to treat cancer by blocking the BCL-2 protein. Technavio's BCL-2 inhibitors market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of BCL-2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as label expansion of venetoclax from monotherapy to combination therapy and high efficacy and tolerability of combination therapy compared with monotherapy will significantly help the market segment in maintaining its leading position. Also, our global BCL-2 inhibitors report has observed market growth factors such as rise in geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors. However, the availability of substitutes, adverse effects of BCL-2 inhibitors, and drug resistance may hamper the growth of the BCL-2 inhibitors industry over the forecast period.

Overview

Growing awareness about hematological malignancies

Most of the times, symptoms of hematological malignancies are mild or not apparent. This may hamper the market growth as the patient may not know how to identify symptoms and opt to visit a specialist. To combat this challenge, many organizations and market vendors have been organizing awareness programs to educate patients about indication symptoms and available diagnostic methods and treatment options. These awareness programs also conduct cancer screening. As a result, appropriate diagnosis and treatment will take place. This will increase sales of BCL-2 inhibitors, which will lead to the expansion of the BCL-2 inhibitors market at a CAGR of almost 39% during 2019-2023.

Development of novel formulations

The only approved therapy available in the market to treat hematological malignancies is venetoclax, which has limited anti-BCL activity. Therefore, vendors have started formulating novel drugs that can be administered in combination with other therapies. These novel drugs are formulated to overcome drug resistance caused by BCL-2 inhibitors and provide enhanced efficacy. As a result, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global BCL-2 (B-cell lymphoma 2) inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global BCL-2 inhibitors market is concentrated. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading BCL-2 inhibitors manufacturers, which include AbbVie Inc. and F. Hoffmann-La Roche Ltd.

Also, the BCL-2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increase of patient assistance programs
  • Strategic alliances
  • Development of novel formulations

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Some of the approved combination therapies
  • Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Prevalence, incidence, and mortality in the US are tabulated as follows.
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: AbbVie Inc. - Vendor overview
  • Exhibit 47: AbbVie Inc. - Business segments
  • Exhibit 48: AbbVie Inc. - Organizational developments
  • Exhibit 49: AbbVie Inc. - Geographic focus
  • Exhibit 50: AbbVie Inc. - Key offerings
  • Exhibit 51: AbbVie Inc. - Key customers
  • Exhibit 52: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 53: F. Hoffmann-La Roche Ltd. - Product segments
  • Exhibit 54: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 55: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 56: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 57: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 58: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 59: Validation techniques employed for market sizing
  • Exhibit 60: Definition of market positioning of vendors
Back to Top